Table II.

Details of intervention studies included.

Location	Subjects	Main outcome measure	Intervention
Tromsø 1, Norway	Subjects with reduced glucose tolerance	Development of type 2 diabetes	20,000 IU vitamin D3 per week or placebo
Tromsø 2, Norway	Subjects with serum 25(OH)D < 50 nmol/l	Blood pressure, lipids, depression	40,000 IU vitamin D3 per week or placebo
Tromsø 3, Norway	Subjects with serum 25(OH)D < 50 nmol/l	Glucose sensitivity	40,000 IU vitamin D3 per week or placebo
Vienna, Austria	Kidney transplant recipients with 25(OH)D < 50 nmol/l	Graft function	6800 IU vitamin D3 per day or placebo
Seattle, USA	Type 2 diabetes with 25(OH) D < 75 nmol/l and urine albumin excretion ≥ 30 mg/day	Urine albumin excretion	2000 IU vitamin D3 per day or placebo
Dundee 1, Scotland	Age > 70 y, isolated systolic hypertension and 25(OH)D < 75 nmol/l	Blood pressure	100,000 units vitamin D3 or placebo, taken at 0, 3, 6, and 9 months
Dundee 2, Scotland	Adults with a past history of myocardial infarction	Change in endothelial function	100,000 units vitamin D3 or placebo, taken at 0, 2, and 4 months
Dundee 3, Scotland	Adults with resistant hypertension and 25(OH)D level < 75 nmol/l	Blood pressure	100,000 units vitamin D3 or placebo, taken at 0, 2, and 4 months
Aarhus, Denmark	Subjects with serum 25(OH) D < 80 nmol/l	PTH and calcium metabolism	2800 IU vitamin D3 per day or placebo
Leuven, Belgium	Patients with moderate to very severe COPD	COPD exacerbations	100,000 units vitamin D3 or placebo every 4 weeks during 1 y

25(OH)D, 25-hydroxyvitamin D; PTH, parathyroid hormone; COPD, chronic obstructive pulmonary disease.